# Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation

> **NCT05162456** · — · UNKNOWN · sponsor: **Collegium Medicum w Bydgoszczy** · enrollment: 250 (estimated)

## Conditions studied

- SARS-CoV2 Infection
- SARS-CoV2 Antibodies

## Interventions

- **DIAGNOSTIC_TEST:** assessment of the anti-SARS-CoV-2 IgG antibody titer in 3-dose schedule
- **DIAGNOSTIC_TEST:** assessment of the anti-SARS-CoV-2 IgG antibody titer in 2-dose schedule

## Key facts

- **NCT ID:** NCT05162456
- **Lead sponsor:** Collegium Medicum w Bydgoszczy
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-01
- **Primary completion:** 2023-02-28
- **Final completion:** 2023-04-30
- **Target enrollment:** 250 (ESTIMATED)
- **Last updated:** 2021-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05162456

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05162456, "Determinants of the Level of Anti-SARS-CoV-2 IgG ANTibodiEs After Vaccination Study in Patients After Organ Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05162456. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*